Explore the Agenda
7:50 am Chair’s Opening Remarks
Networking Session: Navigating Investor Expectations
8:00 am Grant Organisation & Investor Icebreaker: When Being Selective, where will Investors Invest?
- Are there business models for non-dilutive funding?
- How have changes to the barrier to entry for new innovations fed through into investment?
- How to progress discussions with investors. What is expected and helpful to understand from biotech, from the investor perspective?
- How to navigate the grant process?
8:30 am Investors Icebreaker Speed Networking
What is this session?
Following the investor panel, where the audience will understand investor interests, this formal networking ensures that each biotech can introduce itself to each investor
How will this session run?
Join high tables in small groups with an investor at each table. For rounds of five minutes, biotech stays at tables and investors move around. Rapidly gauge alignment between portfolios and the stage of the company, share business cards, or ask a follow-up question from the panel before the investors rotate, and a new round begins
7:30 am One-on-One PartneringTM Portal Opens for Private Meetings
To maximize your opportunity to secure key connections before the conference ends, you can choose to exchange business cards with investors evaluating investments across neuroscience, or continue to meet with pharma and biotech connections in one-to-one meetings arranged through the partnering system
9:00 am Morning Break & Networking Opportunity
9:30 am One-on-One Partnering PortalTM Pauses as Presentations Start
9:45 am Showcase Your Science: Pipeline Innovation Partner Presentations
3rd Presentation Session
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience.
What is this session?
Following the same structure as the two presentation sessions on conference day one, these are further presentation slots, so pharma and investors have more opportunities to listen to pitches from leading biotech across Neuroscience. Whether you are driving a truly transformative therapeutic benefit in rare diseases, addressing residual unmet need in neuroinflammation, or validating new targets in neurodegeneration, this is a more targeted opportunity to share your company profile and differentiation in front of active and interested search and evaluation teams.
11:30 am Lunch Break & Networking Opportunity
11:30 am One-on-One Partnering Portal Opens for Final Meeting Opportunity
12:45 pm Showcase Your Science: Pipeline Innovation Partner Presentations
4th Presentation Session
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience.
What is this session?
To host as many exciting pipeline updates and introductions to exciting new companies as possible, this is an additional session with presentation sessions available to those attending. With attendance still high ahead of the afternoon panel, make sure you join the other presenting organizations with the opportunity to pitch. Don’t leave the conference without advocating for your team and cementing the insights you might have shared during 1-2-1 meetings up until now.
Redefining Target Discovery: Science, Strategy & Smart Partnerships
1:45 pm What is the Direction of New Targets? Different Target Identification Strategies
- Reviewing the state of play of target identification and validation, and business rationale to explore newly discovered targets
- Leveraging human genetic data to understand the efficacy of new drugs
- Discussing the optimal moment for a biotech to partner a novel target identified through an innovative platform and whether the current deal-making landscape is favouring first-in-class or best-in-class
Innovating Access: Structuring Smart Collaborations in Drug Delivery
2:15 pm Understanding Latest Thinking Around Drug Delivery: What is Coming Next?
- How has advancing clinical validation increased deal-making across drug delivery technologies?
- Structuring discussions with tech innovators to understand how best to combine modalities
- Balancing developing a naked asset for a larger partnership versus partnering with a delivery technology to develop